Polycystic ovarian disease (PCOD)—pregnancy rate and outcome in in vitro fertilization

Hull MGR: Polycystic ovarian disease: Clinical aspects and prevalence.In Research and Clinical Forums, ID Cooke, B Lunenfeld (eds). Kent, Royal Wells Medical Press, 1989, pp 21–33Google Scholar

Hammond MG, Halme JK, Talbert LM: Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 1983;62:196–202Google Scholar

Lobo RA, Gysler M, March CM, Boebelsman U, Mishell DR: Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982;37:168–174Google Scholar

Shepard MK, Balmaceda JP, Leija CG: Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril 1979;32:641–645Google Scholar

Rust LA, Israel R, Mishell DR: An individualized graduated therapeutic regimen for clomiphene citrate. Am J Obstet Gynecol 1974;120:785–790Google Scholar

Whitelaw MJ, Kalman CF, Grams LR: The significance of the high ovulation rate versus the low pregnancy rate with Clomid. Am J Obstet Gynecol 1970;107:865–877Google Scholar

Raj SG, Thompson IE, Berger MJ, Taymor ML: Clinical aspects of the polycystic ovary syndrome. Obstet Gynecol 1977;49:552–556Google Scholar

Kelly AC, Jewelewicz, R: Alternate regimens for ovulation induction in polycystic ovarian disease. Fertil Steril 1990;54:195–202Google Scholar

Lobo RA, Granger LR, Davajan V, Mishell DR: An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertil Steril 1982;37:762–766Google Scholar

Garcia-Flores RF, Vazquez-Mendez J: Progressive dosages of clomiphene in hypothalamic anovulation. Fertil Steril 1984;42:543–547Google Scholar

Salat-Baroux J, Alvarez S, Antoine JM, Cornet D, Tibi Ch, Plachot M, Mandelbaum J: Results of IVF in the treatment of polycystic ovary disease. Hum Reprod 1988;3:331–335Google Scholar

Salat-Baroux J, Alvarez S, Antoine JM, Tibi C, Cornet D, Mandelbaum J, Plachot M, Junca AM: Comparison between long and short protocols of LHRH agonist in the treatment of polycystic ovary disease by in-vitro fertilization. Hum Reprod 1988;3:535–539Google Scholar

Ashkenazi J, Feldberg D, Dicker D, Yeshaya A, Ayalon D, Goldman JA: IVF-ET in women with refractory polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1989;30:157–161Google Scholar

Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S: The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: A comparison of results with those of patients with tubal infertility. Hum Reprod 1990;5:816–818Google Scholar

Radwanska E, Rawlins RG, Tummon I, Maclin V, Binor Z, Dmowski WP: Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment. Fertil Steril 1988;49:356–359Google Scholar

Dor J, Shulman A, Pariente C, Bider D, Levran D, Menashe Y, Mashiach S; The effect of gonadotropin-releasing hormone agonist on the ovarian response and in vitro fertilization results in polycystic ovarian syndrome: A prospective study. Fertil Steril (in press)Google Scholar

Fleming R, Harton MJ, Hamilton MPR, McCune GS, Black WP, MacNaugton MC, Couts JRT: Successful treatment of infertile women with oligomenorrhea using a combination of an LHRH agonist and exogenous gonadotrophins. Br J Obstet Gynaecol 1985;92:369–372Google Scholar

Howles CM, Macnamee MC, Edwards RG, Goswamy R, Steptoe PC: Effect of high tonic levels of luteinizing hormone on outcome of in vitro fertilization. Lancet 1986;2:521–522Google Scholar

Tanbo T, Dale PO, Kjekshus E, Haug E, Abyholm T: Stimulation with human menopausal gonadotropin versus folliclestimulating hormone after pituitary suppression in polycystic ovarian syndrome. Fertil Steril 1990;53:798–803Google Scholar

Dale PO, Tanbo T, Abyholm T: In-vitro fertilization in infertile women with the polycystic ovarian syndrome. Hum Reprod 1991;6:238–241Google Scholar